The One Queer Vertical VC Still Funds

queerecon

Oct 22

10 min read

Market Intelligence · Institute for Queer Economics

Pride sponsorships are being cut, DEI budgets are shrinking and LGBTQ+ founders still raise under 1% of venture capital. Yet on 14 October 2026 a virtual LGBTQ+ therapy provider closed a $7m seed round led by a mainstream impact fund. This is why health-tech is the exception, what the investors are actually buying, and what could break it.

The deal in numbers

Allswell is a San Francisco company that delivers virtual therapy, group programmes and trauma-informed care to LGBTQ+ patients in Washington DC, Maryland and Virginia. It launched in spring 2025. Eighteen months later it has around 40 clinicians, hundreds of active patients and more than 1,500 billable sessions a month, and it has just raised $7m from a syndicate led by Rethink Impact (Behavioral Health Business, MobiHealthNews).

Term	Detail
Round	Seed, $7m, announced 14 October 2026
Lead	Rethink Impact; managing partner Heidi Patel joins the board
New investors	Magnify Ventures, Ulu Ventures, Hopelab Ventures
Existing investors	Techstars, Amboy Street Ventures (led the $1.3m pre-seed in October 2025)
Total raised	$8.3m
Founders	Dawn Androphy (CEO) and Connor Gordon (CTO), out of Stanford GSB's Startup Garage and Techstars
Payers	Commercial insurance and Medicaid; about two thirds of patients are covered by Medicaid
Reported outcomes	77% improved on anxiety and 71% on depression at 60 days (company figures, no sample size published)
Retention	Patients often stay over a year, against an industry norm of six to eight sessions (company claim)
Use of funds	Expansion beyond the DC area, psychiatric medication management from 2027, a PTSD curriculum, LGBTQ+-specific clinician training and certification

Three numbers carry the case. Fifteen hundred billable sessions a month from hundreds of patients means the average patient is seen several times a month. A two-thirds Medicaid share means the company reached that scale on the payer most venture-backed mental health start-ups avoid. And if patients really stay over a year against a category norm of six to eight sessions, the revenue earned from each acquired patient is a multiple of a typical teletherapy business. That last figure is the one a lead investor underwrites, and it is the one to treat as a claim until an audited number appears.

Who wrote the cheque

Not one investor in this round is an LGBTQ+-themed fund. That is the signal. The money came from an impact generalist, a youth mental health investor, a family and care economy fund, a sexual health specialist and an accelerator, each of which can justify the cheque on its own thesis without any reference to Pride.

Investor	What it is	Why it is here
Rethink Impact (lead)	Impact venture firm backing technology founders in healthcare, economic opportunity, sustainability and education	Healthcare access thesis; a board seat makes this a conviction lead, not a follow
Hopelab Ventures	Investment arm of Hopelab; seed to Series A companies serving people aged 10 to 25; $20m deployed across 28 companies; portfolio includes Violet, Koko and Blackbird Health	Queer young people are an explicit priority population
Magnify Ventures	Santa Monica early-stage fund for the care economy and family health; cheques of $250k to $2m; portfolio includes Papa and MiSalud	Backs "a model that actually works, reimbursed by insurance, grounded in clinical outcomes" (Julie Wroblewski, Magnify)
Ulu Ventures	Seed fund founded by Miriam Rivera and Clint Korver, known for applying decision analysis to seed investing (Stanford GSB)	Probability-weighted bet on a reimbursed behavioural health model
Amboy Street Ventures	Los Angeles fund, $20m Fund I closed in 2023, founded by Carli Sapir; seed and Series A in women's health and sexual health; portfolio includes Evvy, Hey Jane and Dame	Led the 2025 pre-seed and re-upped; the only specialist in the round, and its specialism is sexual health, not LGBTQ+ identity
Techstars	Accelerator Allswell went through	Pro-rata follow-on

Two things stand out. The specialist that found the company early is a women's and sexual health fund, which tells you LGBTQ+ mental health is now sourced through the sexual and reproductive health pipeline rather than through diversity funds. And Hopelab's participation places Allswell in youth mental health, a category with its own payer momentum, its own policy constituency and a far larger total market than LGBTQ+ care alone.

Compare the 2022 syndicates. FOLX Health's $30m Series B was led by 7wireVentures with Foresite, Bessemer, Define and Polaris. Plume's $24m Series B was led by Transformation Capital with General Catalyst and Town Hall Ventures. Those were marquee digital health names at the top of the cycle. Allswell's syndicate is smaller and more thematic, which is what a seed round in a tighter market looks like. That it closed at all is the point.

Why health-tech still raises when Pride budgets fall

The consumer side of the queer economy has had two bad years. In 2025, Gravity Research found 39% of corporations scaling back external Pride engagement, up from 9% a year earlier. Mastercard, Citi, Pepsi, Nissan and PwC dropped NYC Pride; Anheuser-Busch, Comcast and Diageo left SF Pride (Axios). NYC Pride ran a $750,000 sponsorship shortfall. Some sponsors returned in 2026, Target among them, but Starbucks and Accenture kept their distance and nobody called it a recovery (Fast Company). LGBTQ+ founders were already raising under 1% of venture funding before any of this (StartOut, via Fierce Healthcare).

Against that backdrop, LGBTQ+ health-tech keeps closing rounds. The reason is that its revenue does not depend on anyone's willingness to be seen supporting queer people. It depends on billing codes.

The payer does not care about the politics. A Medicaid managed-care plan or a commercial insurer reimburses a therapy session because a credentialed clinician delivered a covered service to an enrolled member. The identity of the patient and the branding of the provider are irrelevant to the claim. A Pride sponsorship is discretionary marketing spend a CFO can cut in a bad news cycle. A reimbursed claim is a contractual obligation.
Specialisation raises retention, and retention is the whole economics of teletherapy. Generalist platforms lose patients after six to eight sessions. Allswell says its patients stay over a year, and attributes it to clinicians who do not need to be taught what a chosen family is. If that holds at scale, the lifetime value of a patient is several times the category norm.
The demand is measurable, large and under-served. KFF's May 2026 survey of 25,873 adults found 58% of LGBTQ+ adults skipped or postponed needed care in the past year, against 38% of other adults (KFF). Unmet need that insurers already pay for when it is met is the definition of a fundable gap.
Medicaid is a feature, not a compromise. LGBT adults are on Medicaid at 25% against 15% for others (KFF Health Policy 101). A provider that refuses Medicaid, as FOLX does ("Currently, we do not accept Medicaid or Medicare", FOLX support), excludes a quarter of the market before it starts. Allswell built on it.
The category has merged with youth mental health. Hopelab's cheque and the "medical home for LGBTQ+ youth" framing put Allswell in a category with bipartisan payer support and a much larger market than LGBTQ+ care alone.

The shift from the 2021 to 2022 cohort is the real story. FOLX and Plume raised $30m and $24m on subscription and direct-pay models, Plume at $99 a month in most states, and both said they were "working toward" insurance coverage (MobiHealthNews). The 2026 entrant started in-network. That is the move from identity-branded consumer subscriptions to identity-competent reimbursed care. The first model needs cheap capital and willing consumers. The second needs clinical credentialing and payer contracts, which are slower to build and far harder to cut.

The 2022 class and what changed

The venture-backed LGBTQ+ health cohort is small enough to list in full. The pattern is a cycle: large consumer-subscription rounds at the 2021 to 2022 peak, near silence in 2023 and 2024, then a return at seed scale in 2025 and 2026 on an insurance-billed model.

Company	Round	Amount	Date	Lead	Model	Takes Medicaid
Allswell	Seed	$7m	Oct 2026	Rethink Impact	Virtual LGBTQ+ behavioural health, in-network	Yes, about two thirds of patients
Allswell	Pre-seed	$1.3m	Oct 2025	Amboy Street Ventures	As above	Yes
FOLX Health	Series B	$30m	Oct 2022	7wireVentures	Virtual primary care, HRT, PrEP, support groups; subscription and direct-to-employer	No
FOLX Health	Series A	$25m	Feb 2021	Not confirmed	As above	No
Plume	Series B	$24m	Aug 2022	Transformation Capital	Gender-affirming virtual care, $99 a month in most states, "no insurance necessary"	Not at the time
Plume	Series A	$14m	Early 2021	Not confirmed	As above	No
Violet	Seed	$4.1m	Aug 2022	SemperVirens	B2B clinician cultural-competence credentialing; clients include Brightline and Parsley	Not applicable

No FOLX or Plume equity round after 2022 turned up in this research, and neither company has announced Medicaid participation. That absence is itself a data point. The two best-funded names in the category have not raised in four years, and the one new institutional round went to the one company that bills Medicaid.

Two adjacent categories complete the map. Violet, which trains and credentials clinicians in LGBTQ+ competence and sells to health systems, shares an investor with Allswell (Hopelab) and shows the B2B route into the same problem. And general youth mental health, Hopelab's 28 active companies among them, is where Allswell's next comparables will come from, not from the Pride economy.

The demand gap insurers already pay for

On every access measure KFF asked about in May 2026, LGBTQ+ adults are worse off by 9 to 20 percentage points, and the widest gap is the one that matters most to a provider: 58% skipped or postponed care they needed (KFF, August 2026). Each of those skipped visits is a reimbursable service that was not delivered. That is the addressable market for a competent, in-network provider.

The population is larger and younger than most pitch decks assume. Gallup puts LGBTQ+ identification at 9.3% of US adults in 2024, with the share among Gen Z several times that of older cohorts (KFF Health Policy 101). Among 13 to 24 year olds, the Trevor Project's 2025 survey of more than 16,000 LGBTQ+ young people found that 44% of those who wanted mental health care in the past year could not get it, and 36% had seriously considered suicide (Trevor Project, May 2026).

Provider competence is the specific failure. In KFF's 2023 discrimination survey, 61% of LGBT adults who used care reported at least one negative experience with a provider, against 31% of other adults, and about three in ten trans adults had to teach their provider about trans people. This is what a specialist clinician network sells to a payer: fewer dropped patients, fewer wasted first visits and better measured outcomes for a population the plan already covers.

The Medicaid problem

The moat and the exposure are the same thing. Two thirds of Allswell's patients are on Medicaid in the year federal Medicaid policy changed more than at any point since the Affordable Care Act.

Risk	What is known	Exposure
Work requirements	The reconciliation law signed on 4 July 2025 requires states to impose 80-hour-a-month work requirements on Medicaid adults aged 19 to 64, with exceptions, by 31 December 2026; CBO expects federal Medicaid spending cut by over $1 trillion and about 10 million more uninsured by 2034 (Hooper Lundy)	High. DC, Maryland and Virginia all expanded Medicaid, so the adult patient base sits in the affected group
Six-monthly redeterminations	Expansion adults must be re-verified at least every six months for renewals from 31 December 2026	High. Procedural disenrolment churns exactly the long-tenure patients the retention claim depends on
Cost sharing	Up to $35 per service for expansion adults just above the poverty line from October 2028, but mental health and substance use services are exempt	Low. The one clear tailwind in the law
Gender-affirming care politics	27 states restrict such care for minors; federal actions treat it as a breach of Medicare and Medicaid participation conditions (KFF)	Medium. Allswell is a therapy provider, not a prescriber of hormones, but a youth-skewed LGBTQ+ patient base and planned psychiatric medication management put it close to a moving line
Unaudited outcomes	The 77% and 71% improvement figures and the over-a-year tenure are company numbers with no sample size, control or method published	Medium. The next round will be priced on them
Concentration	Hundreds of patients, about 40 clinicians, three jurisdictions, Medicaid as the main scale driver	High. One managed-care contract change in one state could move a third of revenue
Replicability	Generalist teletherapy networks can add an LGBTQ+ clinician filter at near-zero cost	Medium. The defensible asset is the training curriculum, the clinician certification and the outcomes record, which is where the new money is going
Exit path	No FOLX or Plume equity round found since 2022; no LGBTQ+ health-tech exit of note	Medium. The realistic exit is acquisition by a behavioural health platform or a health system

The honest summary is that this is a bet on competent execution inside a shrinking public programme. The business wins if Medicaid churn is survivable because the retention edge is real, and if the commercial payer contracts the company says are "now coming online" diversify the payer mix before the December 2026 redetermination cycle bites. If either fails, the 2027 Series A becomes difficult.

What to take from it

Founders. The fundable LGBTQ+ company in 2026 is one whose revenue is contractual, measurable and indifferent to the news cycle. Build in-network from day one, publish outcomes with sample sizes, and pitch the generalist thesis the money actually holds: youth mental health, the care economy, sexual and reproductive health, health equity. The queer specificity is the operating edge, not the pitch. The European version of this company does not yet exist, partly because statutory insurance systems reimburse differently and partly because nobody has built the clinician credentialing layer. That is an open opportunity.

Investors. The syndicate shows where LGBTQ+ health deals are now sourced: sexual health funds, youth mental health investors and impact generalists, not diversity-themed vehicles. The diligence questions are the ones in the risk table: payer mix by month, Medicaid redetermination churn modelled for 2027, audited outcomes, and clinician cost per session against Medicaid rates in each state.

Policymakers. A reimbursed, queer-competent provider is a market answer to a documented access failure, which makes it a cleaner case for liberal health policy than a subsidy or a mandate. The levers that matter are network adequacy and prompt-pay rules in Medicaid managed care. The December 2026 redetermination cycle will show whether that market can survive public austerity.

The larger point is about the queer economy itself. The parts of it that depended on corporate goodwill, sponsorship and marketing budgets have proved cyclical and politically fragile. The part that sells a measurable service to a payer under contract has not. If there is a lesson for anyone building for LGBTQ+ people in 2026, it is that the durable business is the one that gets paid whether or not anyone wants to be seen paying it.

Sources

Company metrics (sessions, outcomes, retention) are Allswell's own statements as reported by the trade press and are labelled as claims. Survey figures are quoted with fieldwork dates and sample sizes. The lead investors of FOLX's and Plume's 2021 Series A rounds were not confirmed for this piece. All pages were opened on 22 October 2026.